Olsalazine - Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 01:17, 22 October 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChEBI_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 01:17, 22 October 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to verified fields - updated 'ChEBI_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound

Olsalazine
Clinical data

Trade names	Dipentum
AHFS/Drugs.com	Monograph
MedlinePlus	a601088
ATC code	A07EC03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	99%
Elimination half-life	0.9 hours
Identifiers
IUPAC name 5--2-hydroxybenzoic acid
CAS Number	15722-48-2
PubChem CID	6003770
DrugBank	DB01250
ChemSpider	10642377
UNII	ULS5I8J03O
KEGG	D00727
ChEMBL	ChEMBL571540
CompTox Dashboard (EPA)	DTXSID8023391
ECHA InfoCard	100.116.494
Chemical and physical data
Formula	C₁₄H₁₀N₂O₆
Molar mass	302.239g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2
InChI InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N
(what is this?) (verify)

Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease such as Ulcerative Colitis. It is sold under the name Dipentum.

The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt.

Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis.

History

Olsalazine gained Food and Drug Administration (FDA) approval in 1990.

Supply

The drug is supplied by UCB Pharma.

Other indications

The Australian biotech company Giaconda has developed a combination therapy for treating constipation-predominant Irritable Bowel Syndrome that uses olsalazine and the anti-gout drug colchicine.

External links

v t e Antidiarrheals, intestinal anti-inflammatory and anti-infective agents (A07)
Rehydration	Oral rehydration therapy
Intestinal anti-infectives	Antibiotics Amphotericin B Colistin Fidaxomicin Kanamycin Natamycin Neomycin Nystatin Paromomycin Polymyxin B Rifaximin Streptomycin Vancomycin Sulfonamides Phthalylsulfathiazole Succinylsulfathiazole Sulfaguanidine Nitrofuran Nifuroxazide Nifurzide Imidazole Miconazole Arsenical Acetarsol Oxyquinoline Broxyquinoline
Intestinal adsorbents	Charcoal Bismuth (including bismuth subsalicylate, known as Pepto-Bismol) Pectin Kaolin Crospovidone Attapulgite Diosmectite
Antipropulsives (opioids)	Opium tincture (laudanum) Codeine Morphine Camphorated opium tincture (paregoric) crosses BBB: Diphenoxylate (+atropine) Difenoxin does not cross BBB: Eluxadoline Loperamide (+simethicone)
Intestinal anti-inflammatory agents	corticosteroids acting locally Prednisolone Hydrocortisone Prednisone Betamethasone Tixocortol Budesonide Beclometasone antiallergic agents, excluding corticosteroids Cromoglicic acid Aminosalicylates Sulfasalazine Mesalazine Olsalazine Balsalazide
Antidiarrheal micro-organisms	Escherichia coli Saccharomyces boulardii
Other antidiarrheals	Albumin tannate Bismuth subsalicylate Ceratonia Crofelemer Octreotide Racecadotril Kaopectate
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: